Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
19.83
+0.01 (0.05%)
At close: Aug 21, 2026, 4:00 PM EDT
19.72
-0.11 (-0.57%)
Pre-market: Aug 24, 2026, 7:06 AM EDT
Avalo Therapeutics Revenue
Avalo Therapeutics had revenue of $59.00K in the twelve months ending June 30, 2026. In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.
Revenue (ttm)
$59.00K
Revenue Growth
-86.62%
P/S Ratio
18,025.13
Revenue / Employee
$1,788
Employees
33
Market Cap
1.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 59.00K | -382.00K | -86.62% |
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
| Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
| Dec 31, 2017 | 27.81M | 26.66M | 2,312.27% |
| Dec 31, 2016 | 1.15M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 82.76K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Kura Oncology | 77.23M |
| Wave Life Sciences | 65.37M |
| Lexicon Pharmaceuticals | 41.47M |
| Janux Therapeutics | 24.00M |
| Inventiva | 7.94M |
AVTX News
- 17 days ago - Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim - TheFly
- 17 days ago - Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright - TheFly
- 18 days ago - Avalo Therapeutics reports Q2 EPS (83c), consensus (62c) - TheFly
- 18 days ago - Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates - GlobeNewsWire
- 18 days ago - Avalo Therapeutics Quarterly report: Q2 2026 - Filings
- 18 days ago - Avalo Therapeutics Earnings release: Q2 2026 - Filings
- 18 days ago - Avalo Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Avalo Therapeutics to Participate in the BTIG Biotechnology Conference - GlobeNewsWire